Genetic changes in chromosomes 1p and 17p in thyroicl cancer progression

Endocrine Pathology

Volumn 11, Issue 2, 2000, Pages 137-143

  Kleer, Celina G ^a,c   Bryant, Bonita R ^b   Giordano, Thomas J ^a   Sobel, Mark ^b   Merino, Maria J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Anaplastic thyroid carcinoma; Chromosome 1p; Genetic changes; P53; Thyroid neoplasms

Indexed keywords

CELL MARKER; DNA;

ALLELE; ANAPLASTIC CARCINOMA; ARTICLE; CANCER GROWTH; CELL LABELING; CHROMOSOME 17P; CHROMOSOME 1P; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; GENE LOCUS; GENETIC DAMAGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; PRIORITY JOURNAL; PROGNOSIS; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR CELL;

EID: 0033863556     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/ep:11:2:137     Document Type: Article

References (28)

1. 1. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, and Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184,1993.
2. 2. Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary subtype. J Clin Invest 89:1517-122,1992.
3. 3. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G. Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 133:513-522,1995.
4. 4. Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328:170-173,1987.
5. 5. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-1479,1990.
6. 6. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5:565-570,1988.
7. 7. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563,1990.
8. 8. Salvatore D, Celetti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumors; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 134:177-183,1996.
9. 9. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371,1992.
10. 10. Pilotti S, Collini P, Del Bo R, Cattoretti G, Pierotti MA, Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 18(10):1054-1064,1994.
11. 11. Grebe SK, McIver B, Hay ID, et al. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 82:3684-3691,1997.
12. 12. Amler LC, Corvi R, Praml C, et al. A reciprocal translocation (1;15)(36.2;q24) in a neuroblastoma cell line is accompanied by DNA duplication and may signal the site of a putative tumor suppressor gene. Oncogene 10:1095-1101,1995.
13. 13. Bardi G, Pandis N, Fenger C, Kronborg O, Bomme L, Heim S. Deletions in 1p36 as a primary chromosomal aberration in intestinal tumorigenesis. Cancer Res 53:1895-1898,1993.
14. 14. Cheng NC, Van Roy N, Chan A, Beitsma M, et al. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region only one of which is associated with N-myc. Oncogene 10:291-297,1995.
15. 15. Leister I, Weith A, Bruderlein S, et al. Human colorectal cancer: high frequency of deletions at chromosome 1p35. Cancer Res 50:7232-7235,1990.
16. 16. Rosai J, Carcangiu M.L, DeLellis R.A. Tumors of the thyroid gland. In: Rosai, J, ed. Atlas of tumor pathology, 3rd series. Washington, DC: Armed Forces Institute of Pathology, 1992.
17. 17. Zhuang Z, Berttheau P, Emmert-Buck MR, Liotta LA, Gnarra J, Linehan WM, Lubensky IA. A new microdissection technique for archival DNA analysis of specific cell populations in lesions less than one millimeter. Am J Pathol 146:620-625,1990.
18. 18. Jhiang SM, Mazzaferri E.L. The Ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 123:331-337,1994.
19. 19. Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/ret TPC oncogene in human thyroid carcinomas. Oncogene 7:1331-1337,1992.
20. 20. Bongarzone I, Pierotti MA, Monzini N, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4:1457-1462,1989.
21. 21. Takahashi M. Oncogenic activation of the ret protooncogene in thyroid cancer. Crit. Rev. Oncogenesis 6:35-46,1995.
22. 22. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras proro-oncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 71:223-229,1990.
23. 23. Dobashi Y, Sakamoto A, Sugiura H, et al. Overexpression of p53 as a prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381,1993.
24. 24. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327,1993.
25. 25. Lane DP. p53 and human cancers. Br Med Bull 50:582-599,1994.
26. 26. Nakamura T, Yana I, Kobayashi T, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293-1298,1992.
27. 27. Ng IOL, Na J, Lai ECS, Fan ST Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. Am J Clin Pathol 104:313-318,1995.
28. 28. Stravropoulos NE, Ioackim-Velogianni E, Hastazeris K, et al. Growth factors in bladder cancer defined by Ki-67: association with cancer grade category and recurrence rate of superficial lesions. Br J Urol 72:736-739,1993.